Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 34Neoplasms 21Carcinoma, Non-Small-Cell Lung 7Brain Neoplasms 5Skin Neoplasms 4Neoplasm Metastasis 4Glioma 4Thyroid Carcinoma, Anaplastic 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colorectal Neoplasms 2Astrocytoma 2Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Nonseminomatous germ cell tumor 1Neurofibromatosis 1 1Multiple Myeloma 1Melanoma, Cutaneous Malignant 1Leukemia, Hairy Cell 1Gastrointestinal Stromal Tumors 1Fever 1

Interventions

trametinib 1lenvatinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Differentiated Thyroid Cancer (DTC) × dabrafenib × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡